PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
45.50%
ROE 1.25-1.5x AVXL's 37.10%. Bruce Berkowitz would see if management strategy leads to consistently higher returns.
-1797.00%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
192.21%
ROCE above 1.5x AVXL's 37.68%. David Dodd would check if sustainable process or technology advantages are in play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.